Bayer AG (BAYRY) Receives Consensus Rating of “Buy” from Analysts
Bayer AG (NASDAQ:BAYRY) has earned a consensus recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company.
BAYRY has been the subject of a number of analyst reports. Zacks Investment Research lowered Bayer AG from a “hold” rating to a “sell” rating in a research note on Monday, March 27th. Berenberg Bank lowered Bayer AG from a “buy” rating to a “hold” rating in a research note on Monday, July 3rd.
Shares of Bayer AG (BAYRY) opened at 128.80 on Friday. Bayer AG has a 52-week low of $91.53 and a 52-week high of $139.04.
Bayer AG (NASDAQ:BAYRY) last issued its quarterly earnings results on Thursday, April 27th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.40 by $0.40. Bayer AG had a net margin of 16.40% and a return on equity of 24.89%. The business had revenue of $14.11 billion for the quarter, compared to analysts’ expectations of $13.65 billion. On average, analysts forecast that Bayer AG will post $9.12 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/14/bayer-ag-bayry-receives-consensus-rating-of-buy-from-analysts.html.
Bayer AG Company Profile
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.